Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) Director Kevin C. Oboyle sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $40.08, for a total transaction of $300,600.00. Following the sale, the director now owns 19,485 shares in the company, valued at approximately $780,958.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) opened at 39.33 on Thursday. Zeltiq Aesthetics Inc. has a 52-week low of $18.41 and a 52-week high of $40.98. The firm has a 50-day moving average of $37.67 and a 200 day moving average of $30.58. The company has a market capitalization of $1.56 billion, a P/E ratio of 59.14 and a beta of 0.80.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.07. The firm earned $89.50 million during the quarter, compared to analyst estimates of $79.68 million. Zeltiq Aesthetics had a net margin of 9.54% and a negative return on equity of 9.90%. The business’s revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.03 earnings per share. On average, analysts anticipate that Zeltiq Aesthetics Inc. will post ($0.13) EPS for the current year.
A number of equities research analysts have recently issued reports on ZLTQ shares. TheStreet lowered shares of Zeltiq Aesthetics from a “buy” rating to a “hold” rating in a report on Friday, June 10th. Brean Capital restated a “buy” rating and set a $35.00 price target on shares of Zeltiq Aesthetics in a report on Tuesday, June 21st. Leerink Swann restated a “buy” rating on shares of Zeltiq Aesthetics in a report on Thursday, June 30th. Zacks Investment Research lowered shares of Zeltiq Aesthetics from a “hold” rating to a “sell” rating in a report on Thursday, July 14th. Finally, Maxim Group boosted their price target on shares of Zeltiq Aesthetics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $39.89.
Hedge funds have recently made changes to their positions in the stock. FMR LLC increased its stake in shares of Zeltiq Aesthetics by 45.2% in the second quarter. FMR LLC now owns 4,277,811 shares of the company’s stock worth $116,913,000 after buying an additional 1,332,129 shares in the last quarter. BlackRock Fund Advisors increased its stake in shares of Zeltiq Aesthetics by 9.5% in the second quarter. BlackRock Fund Advisors now owns 2,297,982 shares of the company’s stock worth $62,804,000 after buying an additional 199,946 shares in the last quarter. Point72 Asset Management L.P. increased its stake in shares of Zeltiq Aesthetics by 30.7% in the second quarter. Point72 Asset Management L.P. now owns 2,219,762 shares of the company’s stock worth $60,666,000 after buying an additional 521,462 shares in the last quarter. Aisling Capital LLC increased its stake in shares of Zeltiq Aesthetics by 0.3% in the second quarter. Aisling Capital LLC now owns 2,109,727 shares of the company’s stock worth $57,659,000 after buying an additional 6,199 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Zeltiq Aesthetics by 4.1% in the second quarter. Vanguard Group Inc. now owns 1,569,585 shares of the company’s stock worth $42,897,000 after buying an additional 61,700 shares in the last quarter.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.